Investigating how Alzheimer's disease risk genes affect cell metabolism and signaling
The effects of Alzheimer's disease risk genes on metabolism and signaling across cell types
This study is looking at how certain genes linked to Alzheimer's disease affect how our cells work and respond to stress as we age, using special cells made from skin samples, to help find new ways to prevent or treat the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10524301 on NIH RePORTER |
What this research studies
This research explores the impact of specific genetic variants associated with Alzheimer's disease on cellular metabolism and signaling pathways. By utilizing induced pluripotent stem cells (iPSCs) that carry these genetic variants, researchers will analyze how these genes influence different cell types and their responses to aging-related stress. The study employs a systems biology approach, integrating various biological data to uncover the mechanisms that may lead to Alzheimer's disease. This could provide insights into potential therapeutic targets for preventing or treating the disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a family history of Alzheimer's disease or those who carry genetic risk factors such as the APOE4 allele.
Not a fit: Patients who do not have any genetic predisposition to Alzheimer's disease or those with early-onset forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating Alzheimer's disease by targeting the underlying genetic mechanisms.
How similar studies have performed: Previous research has shown promising results in understanding the genetic factors of Alzheimer's disease, indicating that this approach could yield valuable insights.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: Fraenkel, Ernest — Massachusetts Institute of Technology
- Study coordinator: Fraenkel, Ernest
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.